Trial Search Results

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

This is a randomized trial to estimate the activity of R-ICE plus SGN-40 vs. R-ICE plus placebo in patients with DLBCL. The study will assess safety and tolerability and will measure any additional clinical benefit observed in patients receiving SGN-40.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Seagen Inc.

Collaborator: Genentech, Inc.

Stanford Investigator(s):


  • Drug: SGN-40
  • Drug: placebo
  • Drug: rituximab
  • Drug: etoposide
  • Drug: carboplatin
  • Drug: ifosfamide


Phase 2


Inclusion Criteria:

   - Confirmed diagnosis of de novo or transformed DLBCL, or follicular grade 3b lymphoma.

   - Received at least four cycles of first-line therapy with R-CHOP, or equivalent.

   - Best clinical response to first-line therapy of stable disease, partial response, or
   complete response.

   - At least one measureable lesion that is both greater than or equal to 1.5cm by
   radiographic imaging and by positive FDG-PET scan.

Exclusion Criteria:

   - Leptomeningeal or central nervous system lymphoma.

   - Received any therapy for relapsed or progressive disease except for local radiation,
   steroids, or rituximab.

   - Received a hematopoietic stem cell transplant.

Ages Eligible for Study

18 Years - 75 Years

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Sipra Choudhury
Not Recruiting